Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.54% | 53.70 | 0.9% | $1400.96m | |
| JNJ | Johnson & Johnson | 0.66% | 180.65 | 0.7% | $1304.46m | |
| BMY | Bristol-Myers Squibb Co. | -2.28% | 75.83 | 1.0% | $1184.67m | |
| MRK | Merck & Co., Inc. | 0.36% | 92.64 | 0.7% | $1171.07m | |
| ABBV | AbbVie, Inc. | -0.75% | 149.44 | 1.9% | $1092.12m | |
| LLY | Eli Lilly & Co. | 2.44% | 321.11 | 1.1% | $990.82m | |
| AZN | AstraZeneca Plc | 0.73% | 67.19 | 1.0% | $495.11m | |
| BHVN | Biohaven Pharmaceutical Holding Co. Ltd. | 0.06% | 143.27 | 0.0% | $492.89m | |
| NVS | Novartis AG | 0.15% | 91.40 | 0.2% | $260.25m | |
| VERU | Veru, Inc. | 0.71% | 12.73 | 0.0% | $255.51m | |
| GSK | GlaxoSmithKline Plc | -0.95% | 44.00 | 0.2% | $255.16m | |
| HZNP | Horizon Therapeutics Plc | 3.83% | 94.06 | 5.4% | $203.54m | |
| SGEN | Seagen Inc. | 1.74% | 140.87 | 5.7% | $188.90m | |
| NVO | Novo Nordisk A/S | 0.77% | 107.42 | 0.1% | $184.27m | |
| VTRS | Viatris, Inc. | 1.54% | 12.20 | 0.0% | $167.88m |
Company Profile
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.